Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI claim accurately reflects multiple provided label warning/precaution topics and the listed adverse reactions, but it asserts “boxed-warning” content without sufficient boxed-warning-specific label excerpt/section citation in the supplied material.
Category Scores
Accurate Statements
Serious infections are discussed, including advice to avoid use in patients with active serious infection, interrupt therapy for serious/opportunistic infection or sepsis, and monitor for infection.
Section 5.1
TB evaluation/monitoring and viral reactivation management (including consideration of interrupting treatment for herpes zoster) are described.
Section 5.1
Hepatitis B/C initiation is addressed (initiation not recommended in patients with active hepatitis B or hepatitis C).
Section 5.1
Higher all-cause mortality and sudden cardiovascular death are described for oral JAK inhibitor vs TNF blockers, with benefit/risk consideration prior to initiating or continuing therapy.
Section 5.2
Malignancy/lymphoproliferative disorders are discussed, including malignancies/lymphomas, additional risk in smokers, and non-melanoma skin cancers with periodic skin examinations.
Section 5.3
MACE is described (cardiovascular death, non-fatal MI, non-fatal stroke) with patient counseling and discontinuation after MI or stroke.
Section 5.4
Thrombosis (including DVT, PE, arterial thrombosis) is discussed with advice to avoid patients at increased risk and to discontinue if symptoms occur and evaluate/treat appropriately.
Section 5.5
Clinical trial adverse reactions described include herpes zoster and Staphylococcal infection (among others) at <1% in the OPZELURA group and none in the vehicle group.
Section 6.1
Unsupported Statements
OPZELURA label includes boxed-warning content.
The provided excerpts show warning/precaution sections (5.1–5.5) but do not include any explicit boxed warning formatting/section citation indicating a boxed warning is present.
Contradictions
Important Omissions
No contraindications, dosing, administration, or boxed-warning-specific label excerpt is provided to support claims beyond warnings/precautions and adverse reactions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claim largely mirrors safety warning topics and specific listed adverse reactions from the provided label excerpts. The only notable issue is an unsupported assertion that boxed-warning content is present based on the supplied material.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
“Boxed-warning content” is asserted without explicit boxed-warning label excerpt/section support in the provided materials.
Suggested Improvement
Rephrase to “serious warnings and precautions” instead of “boxed-warning content,” or include the specific boxed warning excerpt/section text if available.